{
    "pmcid": "7822889",
    "qa_pairs": {
        "How does the modular nature of the SpyVLP platform benefit the development of nanobodies against emerging SARS-CoV-2 variants?": [
            "It allows for rapid adaptation by altering the RBD sequence.",
            "It enables the production of larger quantities of nanobodies.",
            "It simplifies the purification process of nanobodies.",
            "It enhances the binding affinity of nanobodies to the RBD."
        ],
        "What aspect of the RBD-SpyVLP highlights its potential for global distribution without cold-chain dependence?": [
            "Its stability through lyophilization and freeze-thaw cycles",
            "Its ability to be synthesized at room temperature",
            "Its resistance to high humidity environments",
            "Its formulation as a liquid suspension"
        ],
        "What is the significance of the broad epitope recognition by the RBD-SpyVLP in the context of nanobody design?": [
            "It reduces the risk of neutralization escape mutants.",
            "It enhances the specificity of the immune response.",
            "It limits the vaccine's effectiveness to a single strain.",
            "It increases the likelihood of adverse reactions."
        ],
        "What technology is used to display the receptor-binding domain of the SARS-CoV-2 spike protein on synthetic virus-like particles in the vaccine candidate?": [
            "SpyTag/SpyCatcher technology",
            "CRISPR-Cas9 technology",
            "RNA interference technology",
            "Zinc finger nuclease technology"
        ],
        "Which animal models were used to test the neutralizing antibody responses induced by the RBD-SpyVLP vaccine candidate?": [
            "Mice and pigs",
            "Rabbits and guinea pigs",
            "Monkeys and ferrets",
            "Chickens and rats"
        ]
    }
}